Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyorin Awards Spanish Pharma Rights to Uritos in Latin America
August 2, 2018
- Rxulti Gets European Approval for Schizophrenia: Otsuka/Lundbeck
August 1, 2018
- Takeda Completes TiGenix Acquisition
August 1, 2018
- Lenvima-Keytruda Combo Bags FDA’s Breakthrough Status for Endometrial Carcinoma
August 1, 2018
- Kyowa Hakko Kirin to Be Renamed Kyowa Kirin in July 2019
August 1, 2018
- Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
August 1, 2018
- Kyowa Kirin Sales Sag 2.8% but Net Profit Jumps on Capital Gains
August 1, 2018
- Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
August 1, 2018
- Takeda Integration Team Prepping for Shire Takeover: Weber
August 1, 2018
- AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
August 1, 2018
- Otsuka’s Guadecitabine Misses Primary Targets in Treatment-Naïve AML Patients in PIII
August 1, 2018
- Lonasen Patch Formulation Filed in Japan: Sumitomo Dainippon, Nitto Denko
August 1, 2018
- Eisai Grants Rights for Lorcaserin to Taiwan Biotech in China
August 1, 2018
- ASKA, Laboratoire HRA Strike Deal for IP Rights to Uterine Fibroid Treatment
August 1, 2018
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- Daiichi Sankyo Inks ADC License Pact with Glycotope
July 31, 2018
- Ono Seeks Add’l Indication for Onoact in Ventricular Arrhythmia
July 31, 2018
- Fujifilm to Shutter Gx, LLP Operations in March
July 30, 2018
- Mitsubishi Tanabe’s Erythropoietic Protoporphyria Earns FDA Fast-Track Status
July 30, 2018
- Chugai Forms Partnership with AI Upstart
July 30, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…